📰 Bioscience Inc News
Page 36 - Bioscience Inc News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Bioscience Inc. Real-time updates on events, politics, business and more.
January 12, 2023
U.S. stocks turned higher midway through trading, following the release of inflation data. The Dow traded up 0.62% to 34,182.79 while the NASDAQ ...
January 3, 2023
/PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced...
January 3, 2023
/PRNewswire/ -- The "GMP Cell Therapy Consumables Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Product, Cell Therapy, Process, and End Use"...
January 3, 2023
Dublin, Jan. 03, 2023 (GLOBE NEWSWIRE) -- The "GMP Cell Therapy Consumables Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Product,...
January 3, 2023
/PRNewswire/ -- The "GMP Cell Therapy Consumables Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Product, Cell Therapy, Process, and End Use"...
December 21, 2022
Amendment will reduce Company debt by $35 million and annual interest expense by $5 million Combined with recently announced debt retirement of $125 million, Company debt... #TER #Terrascend #TRSSF
December 19, 2022
TerrAscend (OTCMKTS:TRSSF – Get Rating) and Kalera Public (NASDAQ:KAL – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations. Analyst Ratings This is a breakdown of recent ratings for […]
December 16, 2022
/PRNewswire/ -- The "The Global Market for Polyhydroxyalkanoates (PHA) to 2033" report has been added to ResearchAndMarkets.coms offering....
December 14, 2022
All references in this Item 2 and elsewhere in this Quarterly Report to PURE, we, our, us and the Company refer to PURE Bioscience, Inc., a Delaware corporation, and our wholly owned subsidiary, ETI... | December 14, 2022
December 12, 2022
12.12.2022 - DARE-PDM1 Utilizes Proprietary Hydrogel Technology for Vaginal Delivery of Diclofenac, a Nonsteroidal Anti-Inflammatory; Phase 1 Study Targeted for 2023 2022 Daré Portfolio Accomplishments Include: Two Additional Portfolio Programs (DARE-GML and ...